News and Press Releases

FTI Publishes Full Paper on Fluorous Mixture Synthesis

September 16, 2002
Download this FTI news release (PDF).

Following up on the preliminary work of Curran and co-workers on the concept of fluorous mixture synthesis (FMS), first published in Science (2001, 291, 1766), researchers at Fluorous Technologies, Inc. (FTI) have now published a full paper in the Journal of the American Chemical Society describing the use of this technology in small molecule library synthesis (J. Am. Chem. Soc. 2002, 124, 10443). FMS is FTI's premier technology that provides highly efficient and high quality library synthesis. The September article, entitled "Solution-phase preparation of 560-compound library of individual pure mappicine analogs by fluorous mixture synthesis" describes the successful seven-component, four-step synthesis of 560 mappicine analogs on semi-preparative scale. Key points for successful application of FMS such as library design, tagging strategy, mixture-mode intermediate purification, reaction monitoring, and HPLC demixing were discussed in detail.

Dr. Wei Zhang, Senior Scientist at FTI and lead author on the paper commented, "We were quite pleased to isolate each and every one of the 560 mappicine analogs using fluorous HPLC. This is a testament to both the robustness of solution-phase chemistry as well as the dependability of FMS to deliver single, pure products."

"The successful application of FMS to a targeted library is a major milestone for FTI as a company", said Dr. Philip E. Yeske, Chief Operating Officer of FTI. "The generous support of the NIH SBIR program has allowed us to develop this technology much faster than otherwise would have been possible. More importantly, the recently awarded Phase II grant from the NIH is providing the capital for our researchers to further broaden the commercial applicability of this approach. We'll continue to report to the scientific community on our progress."

FTI (www.fluorous.com) is a Pittsburgh-based chemical technology company focused on the life sciences market. For further information please contact us at bizdev@fluorous.com.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including risks relating to the early stage of products under development; uncertainties related to patent protection; dependence on third parties, including strategic partners, collaborators and key personnel; future capital needs; and risks relating to the development and commercialization, if any, of Fluorous Technologies' proposed products (such as marketing, manufacturing, safety, regulatory, patent or product liability, supply, competition and other risks).